论文部分内容阅读
为了探讨慢性淋巴细胞白血病(CLL)患者白血病细胞内脱氧胞苷激酶(dCK)的基因表达水平与氟达拉滨(flud)耐药的相关性,采用实时定量PCR(RQ-PCR)方法检测30例CLL患者骨髓或外周血标本的dCK mRNA表达,比较Flud敏感与耐药患者dCK表达水平的差异。结果表明:敏感组dCK表达水平高于耐药组(p=0.001),dCK的表达与性别、年龄、Binet分期、IgVH基因突变、CD38、ZAP-70和p53基因突变均无相关性(p>0.05)。结论:dCK表达水平低或缺陷的患者可能对Flud药物有耐药性,而dCK表达的预后意义有待进一步探讨。
To investigate the relationship between gene expression of deoxycytidine kinase (dCK) and fludraben resistance in patients with chronic lymphocytic leukemia (CLL), real-time quantitative PCR (RQ-PCR) The expression of dCK mRNA in bone marrow or peripheral blood of patients with CLL was compared between the Flud-sensitive and drug-resistant patients. The results showed that the expression of dCK in sensitive group was higher than that in drug-resistant group (p = 0.001). There was no correlation between dCK expression and gender, age, Binet stage, IgVH gene mutation, CD38, ZAP- 0.05). Conclusions: Patients with low or defective dCK expression may be drug resistant to Flud, and the prognostic significance of dCK expression remains to be further explored.